Clinical Scorecard: Comparative Analysis of T1 and T2 Metrics in Prostate Cancer Bone Metastases: Evaluating MR Fingerprinting Against Standard MRI Techniques
At a Glance
Category
Detail
Condition
Prostate cancer with metastatic bone disease
Key Mechanisms
Magnetic Resonance Fingerprinting (MRF) for quantitative T1 and T2 relaxation time mapping compared to conventional MRI techniques
Target Population
Male patients with metastatic prostate cancer and active pelvic bone metastases
Care Setting
Clinical imaging setting using 1.5-T MRI scanners integrated into whole-body MRI protocols
Key Highlights
MRF offers faster acquisition and simultaneous co-registered T1 and T2 maps compared to conventional quantitative MRI sequences.
MRF shows high repeatability and reproducibility in measuring relaxation properties relevant to bone metastases.
MRF-derived T1 and T2 measurements were prospectively evaluated pre- and post-treatment to assess treatment response in metastatic bone lesions.
Guideline-Based Recommendations
Diagnosis
Use diffusion-weighted imaging (DWI) and Dixon sequences to identify active bone metastases prior to quantitative T1 and T2 mapping.
Employ MRF sequences to obtain rapid, quantitative T1 and T2 maps covering multiple slices of the lesion.
Management
Integrate MRF into clinical MRI protocols to assess treatment response in bone metastases by monitoring changes in T1 and T2 relaxation times.
Use conventional quantitative MRI sequences (IR-TSE for T1 and DSE for T2) as comparative standards when feasible.
Monitoring & Follow-up
Perform baseline and follow-up MRI scans approximately 2–6 months apart to evaluate treatment-induced changes in bone metastases.
Monitor T1 and T2 relaxation times as potential early biomarkers of tumour viability and treatment response.
Risks
Extended scan time (~15 minutes) added to routine WB-MRI protocols may affect patient compliance.
No contrast agents are required, minimizing risk related to contrast administration.
Patient & Prescribing Data
Male patients with metastatic prostate cancer and pelvic bone metastases undergoing anticancer treatment
MRF enables efficient quantitative imaging to detect treatment-induced changes in bone metastases, potentially improving early response assessment.
Clinical Best Practices
Position axial slices to cover active focal pelvic lesions identified by DWI and Dixon imaging for targeted quantitative assessment.
Match field-of-view and slice location between MRF and conventional MRI sequences to ensure comparability.
Use a 1.5-T MRI system with appropriate coil arrays to optimize image quality and reproducibility.
Limit conventional T1 and T2 acquisitions to reduce total scan time while leveraging MRF for multi-slice coverage.
by Mihaela Rata, Nina Tunariu, Yun Jiang, Julie Hughes, Georgina Hopkinson, Erica Scurr, Jessica M. Winfield, Vikas Gulani, Dow-Mu Koh, Matthew R. Orton
Joint clinical consensus outlines evaluation and management considerations for arrhythmias, coronary atherosclerosis, aortic dilatation, myocardial fibrosis, and related findings in older competitive athletes.
